Comparison · NCT00240331-66895737
Rosuvastatin 10mg vs Placebo: Number of Randomised Participants That Died From Cardiovascular Cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rosuvastatin 10mg vs Placebo: Number of Randomised Participants That Died From Cardiovascular Cause. Trial comparisons, record NCT00240331-66895737. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00240331-66895737
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.233 | 0.212 | 0.256 | wilson | |
| Risk in group 2 | 0.234 | 0.213 | 0.257 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000843 | -0.0323 | 0.0306 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.996 | 0.871 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.995 | 0.835 | 1.19 | log | |
| Number needed to treat, for one fewer participant with the outcome on Rosuvastatin 10mg than on Placebo | 1,190 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rosuvastatin 10mg | Rosuvastatin 10 mg oral tablets | 324 | 1,389 | OG000 |
| Group 2 | Placebo | Matching placebo | 324 | 1,384 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Randomised Participants That Died From Cardiovascular Cause
- Description
- Time frame
- Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
- NCT number
- NCT00240331
- Phases
- PHASE3
- Conditions
- Renal Failure
- Interventions
- 10mg Rosuvastatin, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2009-11-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00240331?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00240331-66895737